{"id":"W2296118977","doi":"10.3109/10428194.2015.1128540","title":"Safety and efficacy of different lenalidomide starting doses in patients with relapsed or refractory chronic lymphocytic leukemia: results of an international multicenter double-blinded randomized phase II trial*","year":2016,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"ca_institutions":"McMaster University; Juravinski Cancer Centre","funders":"National Cancer Institute","keywords":"Lenalidomide; Medicine; Tolerability; Neutropenia; Internal medicine; Discontinuation; Refractory (planetary science); Chronic lymphocytic leukemia; Adverse effect; Gastroenterology; Oncology; Surgery; Leukemia; Chemotherapy; Multiple myeloma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001998647,0.001136468,0.003264289,0.001071236,0.000270625,0.00008531444,0.0007070348,0.0007326555,0.0001167058],"category_scores_gemma":[0.002067752,0.0006873038,0.0004157271,0.0007171004,0.001741818,0.0009605083,0.0006124028,0.0002849013,0.00000675826],"about_ca_system_candidate":true,"about_ca_system_consensus":true,"about_ca_system_score_codex":0.1242274,"about_ca_system_score_gemma":0.03590168,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00385048,"about_ca_topic_score_gemma":0.0004118617,"domain_scores_codex":[0.9905629,0.0007029036,0.003627785,0.001782716,0.00196708,0.001356686],"domain_scores_gemma":[0.9918565,0.00329311,0.001774825,0.001596213,0.0006620474,0.000817285],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8949283,0.001736916,0.000614676,0.0005029995,0.0008659111,0.0002283656,0.001322943,0.00007948845,0.002933754,0.0001329167,0.00004427369,0.0966095],"study_design_scores_gemma":[0.9492813,0.009097452,0.008906893,0.002943665,0.0006286729,0.000120884,0.0001885453,0.01267979,0.01473397,0.00004024065,0.0005758569,0.0008027429],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.993414,0.0005513245,0.00006043912,0.0000958726,0.0003921853,0.004570906,0.0001970387,0.0001382796,0.0005799041],"genre_scores_gemma":[0.9954301,0.002114967,0.000454065,0.0001338146,0.000323945,0.0002105137,0.0002654286,0.0001764545,0.0008907421],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.09580675,"threshold_uncertainty_score":0.9995578,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01989551389267892,"score_gpt":0.3024081237141699,"score_spread":0.282512609821491,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}